Business
Lantheus Reports First Quarter 2023 Financial Results
Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year periodGAAP net loss of $2.8 million for
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year periodGAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year periodGAAP fully diluted net loss per share of $.04 for the first quarter 2023, compared to GAAP fully diluted net income per share of $0.61 in the prior year period; adjusted fully diluted net income per share of $1.47 for the first quarter 2023, compared to adjusted fully diluted net income per share of $0.97 in the prior year periodNet cash provided by operating activities was $108.5 million for the first quarter 2023. Free cash flow was $99.3 million in the first quarter 2023The Company provides second quarter 2023 revenue and adjusted diluted earnings per share guidance; increases full year guidance BEDFORD, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, today reported financial results for its first quarter ended March 31, 2023. The Company’s worldwide revenue for the first quarter of 2023 totaled $300.8 million, compared with $208.9 million for the first quarter of 2022, representing an increase of 44.0% over the prior year period. The Company’s first quarter 2023 GAAP net loss was $2.8 million, or $0.04 per fully diluted share, as compared to GAAP net income of $43.0 million, or $0.61 per fully diluted share for the first quarter of 2022. The Company’s first quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1.47, as compared to $0.97 for the first quarter of 2022, representing an increase of approximately $0.50 from the prior year period. Lastly, net cash provided by operating activities was $108.5 million for the first quarter 2023. Free Cash Flow was $99.3 million in the first quarter of 2023, representing an increase of approximately $92.3 million from the prior year period. “As an innovation driven leader committed to bringing novel radiopharmaceuticals to the healthcare community, we are proud of the positive impact we have made in the lives of more than 1.5 million patients during the first quarter of 20...